Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial

Per Eystein Lønning, Emilio Bajetta, Robin Murray, Michèle Tubiana-Hulin, Peter D. Eisenberg, Elizabeth Mickiewicz, Luigi Celio, Paula Pitt, Monica Mita, Neil K. Aaronson, Camilla Fowst, Alexei Arkhipov, Enrico Di Salle, Anna Polli, Giorgio Massimini

Research output: Contribution to journalArticlepeer-review


Purpose: To evaluate the antitumor activity and toxicity of a new steroidal aromatase inactivator, exemestane, in postmenopausal women with metastatic breast cancer who had progressive disease (PD) after treatment with a nonsteroidal aromatase inhibitor. Patients and Methods: In this phase II trial, eligible patients were treated with exemestane 25 mg daily (n = 241) followed, at the time PD was determined, by exemestane 100 mg daily (n = 58). Results: On the basis of the intent-to-treat analysis by independent review, exemestane 25 mg produced objective responses in 6.6% of patients (95% confidence interval [CI], 3.8% to 10.6%) and overall success (complete response + partial response + no change for 24 weeks or longer) in 24.3% (95% CI, 19.0% to 30.2%). The median durations of objective response and overall success were 58.4 weeks (95% CI, 49.7 to 71.1 weeks) and 37.0 weeks (95% CI, 35.0 to 39.4 weeks), respectively. Increasing the dose of exemestane to 100 mg upon the development of PD produced one partial response (1.7%; 95% CI, 0.0% to 9.2%). Both dosages were well tolerated and were discontinued because of adverse events in only 1.7% of patients. Conclusion: Exemestane 25 mg once daily seems to be an attractive alternative to chemotherapy for the treatment of patients with metastatic breast cancer after multiple hormonal therapies have failed. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish
Pages (from-to)2234-2244
Number of pages11
JournalJournal of Clinical Oncology
Issue number11
Publication statusPublished - Jun 2000

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial'. Together they form a unique fingerprint.

Cite this